401 related articles for article (PubMed ID: 16021676)
1. Different proportions of aneusomic cells in ovarian inclusion cysts associated with serous borderline tumours and serous high-grade carcinomas support different pathogenetic pathways.
Körner M; Burckhardt E; Mazzucchelli L
J Pathol; 2005 Sep; 207(1):20-6. PubMed ID: 16021676
[TBL] [Abstract][Full Text] [Related]
2. Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma.
Salvador S; Rempel A; Soslow RA; Gilks B; Huntsman D; Miller D
Gynecol Oncol; 2008 Sep; 110(3):408-17. PubMed ID: 18597838
[TBL] [Abstract][Full Text] [Related]
3. [Molecular carcinogenesis of ovarian carcinoma].
Diebold J
Verh Dtsch Ges Pathol; 2005; 89():77-83. PubMed ID: 18035676
[TBL] [Abstract][Full Text] [Related]
4. Fallopian tube precursors of ovarian low- and high-grade serous neoplasms.
Vang R; Shih IeM; Kurman RJ
Histopathology; 2013 Jan; 62(1):44-58. PubMed ID: 23240669
[TBL] [Abstract][Full Text] [Related]
5. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary.
Leonhardt K; Einenkel J; Sohr S; Engeland K; Horn LC
Int J Gynecol Pathol; 2011 Sep; 30(5):417-24. PubMed ID: 21804388
[TBL] [Abstract][Full Text] [Related]
6. Oviductal glycoprotein, a new differentiation-based indicator present in early ovarian epithelial neoplasia and cortical inclusion cysts.
Woo MM; Gilks CB; Verhage HG; Longacre TA; Leung PC; Auersperg N
Gynecol Oncol; 2004 May; 93(2):315-9. PubMed ID: 15099939
[TBL] [Abstract][Full Text] [Related]
7. Patterns of stromal invasion in ovarian serous tumors of low malignant potential (borderline tumors): a reevaluation of the concept of stromal microinvasion.
McKenney JK; Balzer BL; Longacre TA
Am J Surg Pathol; 2006 Oct; 30(10):1209-21. PubMed ID: 17001150
[TBL] [Abstract][Full Text] [Related]
8. Location of inclusion cysts in mouse ovaries in relation to age, pregnancy, and total ovulation number: implications for ovarian cancer?
Tan OL; Hurst PR; Fleming JS
J Pathol; 2005 Mar; 205(4):483-90. PubMed ID: 15685692
[TBL] [Abstract][Full Text] [Related]
9. High-grade ovarian serous carcinoma exhibits significantly higher p16 expression than low-grade serous carcinoma and serous borderline tumour.
O'Neill CJ; McBride HA; Connolly LE; Deavers MT; Malpica A; McCluggage WG
Histopathology; 2007 May; 50(6):773-9. PubMed ID: 17493241
[TBL] [Abstract][Full Text] [Related]
10. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms.
O'Neill CJ; Deavers MT; Malpica A; Foster H; McCluggage WG
Am J Surg Pathol; 2005 Aug; 29(8):1034-41. PubMed ID: 16006797
[TBL] [Abstract][Full Text] [Related]
11. Detailed morphology of human ovarian surface epithelium focusing on its metaplastic and neoplastic capability.
Okamura H; Katabuchi H
Ital J Anat Embryol; 2001; 106(2 Suppl 2):263-76. PubMed ID: 11732586
[TBL] [Abstract][Full Text] [Related]
12. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
Dehari R; Kurman RJ; Logani S; Shih IeM
Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266
[TBL] [Abstract][Full Text] [Related]
13. p53 protein expression in putative precursor lesions of epithelial ovarian cancer.
Hutson R; Ramsdale J; Wells M
Histopathology; 1995 Oct; 27(4):367-71. PubMed ID: 8847068
[TBL] [Abstract][Full Text] [Related]
14. Early form of ovarian cancer originating in inclusion cysts. A case report.
Aoki Y; Kawada N; Tanaka K
J Reprod Med; 2000 Feb; 45(2):159-61. PubMed ID: 10710752
[TBL] [Abstract][Full Text] [Related]
15. Numerical abnormalities of chromosomes 1, 11, 17, and X are associated with stromal invasion in serous and mucinous epithelial ovarian tumours.
Evans MF; McDicken IW; Herrington CS
J Pathol; 1999 Sep; 189(1):53-9. PubMed ID: 10451488
[TBL] [Abstract][Full Text] [Related]
16. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
Bonome T; Lee JY; Park DC; Radonovich M; Pise-Masison C; Brady J; Gardner GJ; Hao K; Wong WH; Barrett JC; Lu KH; Sood AK; Gershenson DM; Mok SC; Birrer MJ
Cancer Res; 2005 Nov; 65(22):10602-12. PubMed ID: 16288054
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic oophorectomy: a morphologic and immunohistochemical study.
Schlosshauer PW; Cohen CJ; Penault-Llorca F; Miranda CR; Bignon YJ; Dauplat J; Deligdisch L
Cancer; 2003 Dec; 98(12):2599-606. PubMed ID: 14669279
[TBL] [Abstract][Full Text] [Related]
18. Chromosomal losses of regions on 5q and lack of high-level amplifications at 8q24 are associated with favorable prognosis for ovarian serous carcinoma.
Staebler A; Karberg B; Behm J; Kuhlmann P; Neubert U; Schmidt H; Korsching E; Bürger H; Lelle R; Kiesel L; Böcker W; Shih IeM; Buchweitz O
Genes Chromosomes Cancer; 2006 Oct; 45(10):905-17. PubMed ID: 16845658
[TBL] [Abstract][Full Text] [Related]
19. Interphase fluorescence in situ hybridization studies of ovarian adenocarcinomas using the midisatellite probe.
Kalir T; Eisberg A; Dottino P; Cohen C
Gynecol Oncol; 1999 Feb; 72(2):208-14. PubMed ID: 10021303
[TBL] [Abstract][Full Text] [Related]
20. Metallothionein expression and nuclear size in benign, borderline, and malignant serous ovarian tumours.
Tan Y; Sinniah R; Bay BH; Singh G
J Pathol; 1999 Sep; 189(1):60-5. PubMed ID: 10451489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
